Evidence map›Paper›PMID 19884662›Full record

ReviewThe Journal of clinical investigation2009

Acromegaly pathogenesis and treatment.

Shlomo Melmed

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of clinical investigation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04998500 (Growth Hormone as a Model for Reversible Activation of Adipose Tissue Fibrosis), which is not on this map. Cited by 298 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
298citing papers in PubMed, 7 pooled it
21.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04998500 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Growth Hormone as a Model for Reversible Activation of Adipose Tissue Fibrosis

TypeinterventionalSponsorUniversity of AarhusRan2021 to 2023Enrolled10ConditionsFibrosisArmsGrowth hormone, saline and GH receptor blockade (Pegvisomant)
3 · Its place in the literature

Who cites it

298 citing papers in PubMed, 7 syntheses or guidelines pooled it, 677 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Familial acromegaly with a novelJCEM case reports · 2026
    Article
  16. Review
  17. Article
  18. Article
  19. Pathogenesis of nonfamilial somatotroph adenomas.The Journal of clinical endocrinology and metabolism · 2026
    Review
  20. Current controversies in acromegaly care.The Journal of clinical endocrinology and metabolism · 2026
    Review

238 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Shlomo MelmedDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA. Melmed@csmc.edu
Cedars-Sinai Medical Center · US

Funding

Mechanisms of Pituitary TumorigenesisR01CA075979 · NCI · CEDARS-SINAI MEDICAL CENTER · PI MELMED, SHLOMO · 1999 to 2012
$3.5M
NCI NIH HHS CA 075979NCI NIH HHS R01 CA075979
6 · The paper itself

Abstract

Dysregulated growth hormone (GH) hypersecretion is usually caused by a GH-secreting pituitary adenoma and leads to acromegaly - a disorder of disproportionate skeletal, tissue, and organ growth. High GH and IGF1 levels lead to comorbidities including arthritis, facial changes, prognathism, and glucose intolerance. If the condition is untreated, enhanced mortality due to cardiovascular, cerebrovascular, and pulmonary dysfunction is associated with a 30% decrease in life span. This Review discusses acromegaly pathogenesis and management options. The latter include surgery, radiation, and use of novel medications. Somatostatin receptor (SSTR) ligands inhibit GH release, control tumor growth, and attenuate peripheral GH action, while GH receptor antagonists block GH action and effectively lower IGF1 levels. Novel peptides, including SSTR ligands, exhibiting polyreceptor subtype affinities and chimeric dopaminergic-somatostatinergic properties are currently in clinical trials. Effective control of GH and IGF1 hypersecretion and ablation or stabilization of the pituitary tumor mass lead to improved comorbidities and lowering of mortality rates for this hormonal disorder.

Indexed as

AcromegalyAnimalsGrowth HormoneGrowth Hormone-Secreting Pituitary AdenomaHumansInsulin-Like Growth Factor IMorbiditySignal TransductionGrowth HormoneInsulin-Like Growth Factor I

Identifiers

PMID19884662
PMCPMC2769196
OpenAlexW2159303404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.